Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Emily Fusco
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q1 (6 quarters; questions recorded in 4).
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 4with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 2 companies
IFFInternational Flavors & Fragrances3 questions · 3 reporting periods · 0 of 3 challenging
Calendar 2026 Q1
Do you still expect North American health trends to improve starting in the back half of the year with a full recovery in 2027?
Show response
Erik confirmed H1 2026 health business flattish, H2 return to growth, acceleration into 2027. Very pleased with new leadership team and positive customer feedback on commercial and innovation pipeline progress.
Calendar 2025 Q3
are we still on track for an update on this business with the Q4 earnings call in February? And also just a follow-up, have you begun to engage with private equity and strategics on this business?
Show response
Erik confirmed February update on track and revealed strong inbound interest from both PE and strategics. Emphasized ongoing margin transformation progress strengthens the business for any outcome.
Calendar 2024 Q4
what are your expectations for input inflation this year? And how should we expect net pricing to develop through the year
Show response
DeVeau detailed input cost trends by segment: modest inflation in taste and scent from natural ingredients, slight deflation in food ingredients, flat in HNB. Pricing expected consistent across quarters.
CTVACorteva1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q1
With the likely further share shift in Chinese soybean imports from the US to Brazil, how is Corteva positioned for this?
Show response
Chuck noted 50% of US soybeans exported, with China/Mexico/EU taking 65% of exports. Judd quantified 1M acre corn-soy shift = $10-15M EBITDA shift favorable to Corteva.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| IFF International Flavors & Fragrances | 3 | 0%none of 3 questions |
| CTVA Corteva | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | No questions recorded | — | — |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | No questions recorded | — | — |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q2No questions recorded
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q4No questions recorded
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Demand1
- Competitive Dynamics1
- M&A1
- Capital Allocation1
- Trade Tariffs1
- Geographic Expansion1
- Cost Pressure1
- Pricing1